CMS Suggests “Pay For Performance” Approach To Cancer Drug Coverage

The ideal approach to cancer drug reimbursement would tie payment to patient outcomes, Centers for Medicare & Medicaid Services Administrator Mark McClellan said June 15 at a Manhattan Institute luncheon in New York